JPY OF PAPERS

Please type a plus sign (+) inside this box  $\rightarrow$ 

+

PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 atent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Date January 11, 2002

Under the Paperwork Reduction Act of 1995, no persons are required collection of information unless it displays a valid OMB control number. Application Number 09/875,349 TRANSMITTAL Filing Date June 5, 2001 FEB I I 2002 **FORM** First Named Inventor HISERODT, JOHN C Group Art Unit TECH CENTER 1600/2900 1642 (to be used for all correspondence after initial filing) **Examiner Name** G. Bansal Total Number of Pages in This Submission Attorney Docket Number **IRVN-001DIV** ENCLOSURES (check all that apply) Fee Transmittal Form Assignment Papers After Allowance Communication (for an Application) Fee Attached to Group Drawing(s) Appeal Communication to Board Amendment / Reply of Appeals and Interferences Licensing-related Papers After Final Appeal Communication to Group Affidavits/declaration(s) Petition (Appeal Notice, Brief, Reply Brief) **Extension of Time Request** Proprietary Information Petition to Convert to a **Provisional Application Express Abandonment Request** Power of Attorney, Revocation Status Letter Change of Correspondence Information Disclosure Statement X Address Other Enclosure(s) (please Certified Copy of Priority identify below): Terminal Disclaimer **Documents** Return Postcard Request for Refund Response to Missing Parts/ Incomplete Application CD, Number of CD(s) Response to Missing Parts Remarks under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm CAROL L. FRANCIS, Reg. No. 36,513 Individual Name Signature Date January 11, 2002 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: January 11, 2002. Signature

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United Soles Posed Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on this date. TECH CENTER 1600/2900 **Typed or Printed Name** Steven Goldstein Signature Date January 11,2002 IRVN001DIV Attorkey Docket First Named Inventor Hiserodt et al. INFORMATION **Application Number** 09/875,349 DISCLOSURE STATEMENT Confirmation No. 8040 Filing Date June 5, 2001 Address to: Commissioner for Patents Group Art Unit 1642 Washington, D.C. 20231 **Examiner Name** G. Bansal Title Cancer Immunotherapy Using Autologous Tumor Cells Combined with Allogenic Cytokine Secreting Cells

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

All of the references identified herein were disclosed in parent application Serial No. 08/901,225, now U.S. Patent No. 6,277,368B1, and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except as noted below.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged thereon to order No. IRVN001DIV.

Date:

BOZICEVIC, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\IRVN (UC Irvine)\001div\IDS - before 1st OA1.doc

Respectfully submitted,

BOZICEVIC, FIELD & FRANCIS LLP

By:

Carol L. Francis

Registration No. 36,5/3